Compare Microsoft (MSFT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Spyre Therapeutics Inc. Common Stock — how do they compare? Microsoft trades at $529.35 (market cap $4.04T), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Microsoft is far larger — about 537.2× Spyre Therapeutics Inc. Common Stock's market cap, and Microsoft pays a 0.72% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MSFT | SYRE | |
|---|---|---|
Market Cap | $4.04T | $7.52B |
Volume | 23,799,223 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $543.45 | $108.92 |
52-Week Low | $352.83 | $22.18 |
Typical Hold Time | 142 Days | 0 Days |
Enterprise Value | $4.02T | $6.52B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $533.69, down 1.38% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $530 and resistance at $544, while valuation metrics like P/E of 30.28 reflect premium pricing. Recent analyst coverage remains overwhelmingly positive with 82% buy ratings and a $574.50 consensus price target, indicating 7.6% upside potential from current levels.
Outlook remains favorable with AI-driven growth catalysts from Azure and Copilot, though risks include elevated capital expenditures and competitive pressures. The company's strong cash flow generation ($136.16B operating cash flow in 2025) and declining debt-to-asset ratio (6.97% in 2025) provide financial stability. Investors should monitor Q3 2026 earnings against the $4.72 EPS expectation for continued momentum validation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
